Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC
TPC appears to be effective for HNSCC before surgery, and pathologic responses may inform clinical outcomes. Pathologic response criteria defined in this study can establish a standardized and uniform approach for assessment after neoadjuvant treatment for HNSCC.
Authors
- Gabriel Raab
- David G. Pfister (ORCID: https://orcid.org/0000-0002-2109-3221)
- Bin Xu (ORCID: https://orcid.org/0000-0003-4638-9835)
- Giovanna Luiza Caxeiro (ORCID: https://orcid.org/0009-0004-0093-0862)
- Kenric Tam (ORCID: https://orcid.org/0000-0003-3203-3280)
- Jennifer R. Cracchiolo (ORCID: https://orcid.org/0000-0003-4496-906X)
- Nora Katabi (ORCID: https://orcid.org/0000-0003-2974-3046)
- Alan Loh Ho (ORCID: https://orcid.org/0000-0002-6885-3742)
- Lara Ann Dunn (ORCID: https://orcid.org/0000-0001-5318-2571)
- Snjezana Doğan (ORCID: https://orcid.org/0000-0002-4905-8946)
- Eric Jeffrey Sherman (ORCID: https://orcid.org/0000-0002-4960-4783)
- Anas Alabkaa (ORCID: https://orcid.org/0000-0001-5338-2944)
- Ian Ganly (ORCID: https://orcid.org/0000-0001-7636-5426)
- Snehal G. Patel (ORCID: https://orcid.org/0000-0001-9775-5132)
- Ronald Ghossein (ORCID: https://orcid.org/0000-0003-2802-8489)
- Winston Wong
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- Presbyterian Hospital (US)
Publication Details
- Journal
- Otolaryngology
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1002/ohn.70051
- Citations
- 1
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.85